Mark Carbeau is the CEO of BacterioScan. Secondary bacterial infections that are a key contributor to Covid-19 morality, but also are a perennial mainstay with at least 25,000 deaths each year in the US alone. Superbugs and resistance are a greater threat in this cycle than the virus alone, particularly in longer term health care settings. So we need to:
a) fix economic model for antibiotic development, and
b) advance diagnostic platforms to provide physicians answers before antibiotics. To treat sooner and treat appropriately. And the two needs should be linked